Get the Stockscreener App
184.13
6.81%
-13.45
After Hours:
186.99
2.86
+1.55%
Praxis Precision Medicines Inc stock is traded at $184.13, with a volume of 707.17K.
It is down -6.81% in the last 24 hours and down -3.08% over the past month.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.
See More
Previous Close:
$197.58
Open:
$194.82
24h Volume:
707.17K
Relative Volume:
0.88
Market Cap:
$4.94B
Revenue:
$1.77M
Net Income/Loss:
$-123.74M
P/E Ratio:
-20.08
EPS:
-9.17
Net Cash Flow:
$-95.21M
1W Performance:
+0.31%
1M Performance:
-3.08%
6M Performance:
+397.38%
1Y Performance:
+157.49%
1-Day Range:
$181.74
$195.58
1-Week Range:
$175.79
$198.43
52-Week Range:
$26.70
$206.71
Praxis Precision Medicines Inc Stock (PRAX) Company Profile
Name
Praxis Precision Medicines Inc
Sector
Industry
Phone
617-300-8460
Address
99 HIGH STREET, 30TH FLOOR, BOSTON
Compare PRAX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PRAX
Praxis Precision Medicines Inc
|
184.13 | 4.94B | 1.77M | -123.74M | -95.21M | -9.17 |
|
ARGX
Argen X Se Adr
|
918.53 | 57.24B | 3.06B | 1.28B | 447.35M | 19.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
435.52 | 110.12B | 11.74B | 3.68B | 3.34B | 14.19 |
|
INSM
Insmed Inc
|
201.62 | 42.10B | 447.02M | -1.18B | -906.14M | -6.1812 |
|
ONC
Beone Medicines Ltd Adr
|
363.92 | 41.68B | 4.98B | 69.59M | 525.67M | 0.5197 |
|
REGN
Regeneron Pharmaceuticals Inc
|
725.34 | 74.02B | 14.25B | 4.58B | 3.88B | 41.77 |
Praxis Precision Medicines Inc Stock (PRAX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-02-25 | Resumed | Oppenheimer | Outperform |
| May-07-25 | Initiated | Chardan Capital Markets | Buy |
| Mar-03-25 | Reiterated | H.C. Wainwright | Buy |
| Feb-11-25 | Initiated | Deutsche Bank | Buy |
| Aug-05-24 | Initiated | Oppenheimer | Outperform |
| Jun-24-24 | Initiated | Needham | Buy |
| Jun-18-24 | Initiated | Guggenheim | Buy |
| May-01-24 | Initiated | Robert W. Baird | Outperform |
| Sep-19-23 | Initiated | Truist | Buy |
| Jun-06-22 | Downgrade | Wedbush | Outperform → Neutral |
| Dec-16-21 | Initiated | H.C. Wainwright | Buy |
| Aug-26-21 | Initiated | BofA Securities | Buy |
| Apr-26-21 | Initiated | William Blair | Outperform |
| Nov-11-20 | Initiated | Wedbush | Outperform |
| Nov-10-20 | Initiated | Cowen | Outperform |
| Nov-10-20 | Initiated | Evercore ISI | Outperform |
| Nov-10-20 | Initiated | Piper Sandler | Overweight |
View All
Praxis Precision Medicines Inc Stock (PRAX) Latest News
Commit To Purchase Praxis Precision Medicines At $100, Earn 27.5% Using Options - Nasdaq
Praxis Precision Medicines (PRAX) Price Target Increased by 11.27% to 287.79 - Nasdaq
Is Praxis Precision Medicines Inc. stock a contrarian buyJuly 2025 Weekly Recap & Reliable Intraday Trade Plans - newser.com
Published on: 2025-11-16 15:28:41 - newser.com
What valuation multiples suggest for Praxis Precision Medicines Inc. stockIPO Watch & Entry Point Strategy Guides - newser.com
Can Praxis Precision Medicines Inc. stock deliver surprise earnings beatWeekly Profit Summary & Low Risk High Win Rate Picks - newser.com
Using fundamentals and technicals on Praxis Precision Medicines Inc.Weekly Volume Report & Target Return Focused Picks - newser.com
How analysts rate Praxis Precision Medicines Inc. stock todayFed Meeting & Daily Chart Pattern Signal Reports - newser.com
Certain Stock Options of Praxis Precision Medicines, Inc. are subject to a Lock-Up Agreement Ending on 16-NOV-2025. - MarketScreener
How institutional buying supports Praxis Precision Medicines Inc. stock2025 Trading Volume Trends & Accurate Trade Setup Notifications - newser.com
Published on: 2025-11-15 06:25:23 - newser.com
What institutional flow reveals about Praxis Precision Medicines Inc.2025 Technical Patterns & Expert Approved Momentum Ideas - newser.com
HC Wainwright & Co. Maintains Praxis Precision Medicines (PRAX) Buy Recommendation - Nasdaq
Using Python tools to backtest Praxis Precision Medicines Inc. strategiesMarket Growth Summary & Weekly Setup with High ROI Potential - newser.com
PRAX: HC Wainwright & Co. Raises Price Target to $258 | PRAX Sto - GuruFocus
Published on: 2025-11-12 17:26:58 - newser.com
Published on: 2025-11-12 08:52:54 - newser.com
How Praxis Precision Medicines Inc. stock valuations compare to rivalsWeekly Earnings Recap & Community Verified Trade Signals - newser.com
(PRAX) Movement as an Input in Quant Signal Sets - news.stocktradersdaily.com
Published on: 2025-11-09 22:42:30 - newser.com
Praxis Precision Medicines Reports Q3 2025 Financial Results - MSN
Published on: 2025-11-08 04:02:56 - newser.com
Deutsche Bank Adjusts Praxis Precision Medicines Price Target to $270 From $280, Maintains Buy Rating - MarketScreener
Praxis Precision Medicines (PRAX) Is Up After Positive Ulixacaltamide Trial and FDA Alignment on RelutrigineHas the Investment Thesis Gained New Momentum? - Sahm
Does Praxis Precision Medicines Inc. qualify in momentum factor screeningTrade Risk Report & Risk Adjusted Buy and Sell Alerts - newser.com
Oppenheimer Lifts Price Target for Praxis Medicines (PRAX), Keeps Outperform Rating - MSN
Wedbush Maintains Praxis Precision Medicines (PRAX) Underperform Recommendation - Nasdaq
Guggenheim raises Praxis Precision Medicines stock price target on CNS pipeline - Investing.com Canada
Guggenheim raises Praxis Precision Medicines stock price target on CNS pipeline By Investing.com - Investing.com South Africa
Praxis Precision Medicines Inc Stock (PRAX) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.08%
0.19%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):